The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Nicolopoulos K, Moshi MR, Stringer D, Ma N, Jenal M, Vreugdenburg T
Record ID 32018004626
English
Details
Project Status:
Completed
Year Published:
2023
URL for published report:
https://doi.org/10.1007/s11657-023-01211-3
Requestor:
Arch Osteoporos, 18(1), 18.
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
Pubmed ID:
36624318
MeSH Terms
- Bone Density
- Bone Density Conservation Agents
- Osteoporosis
- Denosumab
- Diphosphonates
- Selective Estrogen Receptor Modulators
- Neoplasms
- Ibandronic Acid
- Hormones
- Risedronic Acid
- Zoledronic Acid
Contact
Organisation Name:
Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
Contact Address:
ASERNIP-S 24 King William Street, Kent Town SA 5067 Australia Tel: +61 8 8219 0900
Contact Name:
racs.asernip@surgeons.org
Contact Email:
racs.asernip@surgeons.org
Copyright:
Australian Safety and Efficacy Register of New Interventional Procedures - Surgical
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.